These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27154527)

  • 21. Recurrent Torsades with Refractory QT Prolongation in a 54-Year-Old Man.
    Guess J; Hubel K; Wiggins A; Madigan CG; Bunin J
    Am J Case Rep; 2018 Dec; 19():1515-1518. PubMed ID: 30568157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
    Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
    Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluconazole-associated QT interval prolongation and Torsades de Pointes in a paediatric patient.
    Ünal Yüksekgönül A; Ertuğrul İ; Karagöz T
    Cardiol Young; 2021 Dec; 31(12):2035-2037. PubMed ID: 34024302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of methadone-induced torsades de pointes with lidocaine.
    Rajpal S; Mundi AS; Reddy PC; Akkus NI
    J La State Med Soc; 2013; 165(6):338-41. PubMed ID: 25073261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New data on the antiarrhythmic value of parenteral magnesium treatment: magnesium and ventricular arrhythmias.
    Perticone F; Ceravolo R; De Novara G; Torchia L; Cloro C
    Magnes Res; 1992 Dec; 5(4):265-72. PubMed ID: 1296762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Torsades de Pointes with QT prolongation related to donepezil use.
    Takaya T; Okamoto M; Yodoi K; Hata K; Kijima Y; Nakajima H; Nishikawa Y; Kita T; Ito M; Seo T; Kawashima S
    J Cardiol; 2009 Dec; 54(3):507-11. PubMed ID: 19944332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in acute myelogenous leukemia.
    Otsuka M; Kanamori H; Sasaki S; Taguchi J; Harano H; Ogawa K; Matsuzaki M; Mohri H; Okubo T; Sumita S; Ochiai H
    Intern Med; 1997 Oct; 36(10):705-8. PubMed ID: 9372331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Torsade de pointes and QT syndrome].
    Haverkamp W; Hördt M; Borggrefe M; Breithardt G
    Med Klin (Munich); 1995 Apr; 90(4):240-5. PubMed ID: 7776938
    [No Abstract]   [Full Text] [Related]  

  • 29. Torsades de pointes related to transient marked QT prolongation following successful emergent percutaneous coronary intervention for acute coronary syndrome.
    Kawabata M; Hirao K; Takeshi S; Sakurai K; Inagaki H; Hachiya H; Isobe M
    J Electrocardiol; 2008; 41(2):117-22. PubMed ID: 18328336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Classification and treatment of torsades de pointes (TdP): a report of 11 cases].
    Mei KZ; Sun AH; Li BJ
    Zhonghua Nei Ke Za Zhi; 1993 Jan; 32(1):28-30. PubMed ID: 8404313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. QT interval prolongation, torsade de pointes and renal disease.
    Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
    Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined pharmacological block of I(Kr) and I(Ks) increases short-term QT interval variability and provokes torsades de pointes.
    Lengyel C; Varró A; Tábori K; Papp JG; Baczkó I
    Br J Pharmacol; 2007 Aug; 151(7):941-51. PubMed ID: 17533421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
    Jacobson I; Carlsson L; Duker G
    J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripartum cardiomyopathy presenting with syncope due to Torsades de pointes: a case of long QT syndrome with a novel KCNH2 mutation.
    Nishimoto O; Matsuda M; Nakamoto K; Nishiyama H; Kuraoka K; Taniyama K; Tamura R; Shimizu W; Kawamoto T
    Intern Med; 2012; 51(5):461-4. PubMed ID: 22382559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Torsades de pointes].
    Guize L; Iliou MC; Bayet G; Lavergne T; Le Heuzey JY
    Arch Mal Coeur Vaiss; 1993 May; 86(5 Suppl):769-76. PubMed ID: 8267505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electrocardiographic predictors of bradycardia-induced torsades de pointes in patients with acquired atrioventricular block.
    Cho MS; Nam GB; Kim YG; Hwang KW; Kim YR; Choi H; Kim SH; Rhee KS; Kim NJ; Kim JS; Kim J; Choi KJ; Kim YH
    Heart Rhythm; 2015 Mar; 12(3):498-505. PubMed ID: 25460857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Citalopram induced torsade de pointes, a rare life threatening side effect.
    Kanjanauthai S; Kanluen T; Chareonthaitawee P
    Int J Cardiol; 2008 Dec; 131(1):e33-4. PubMed ID: 17919753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of atropine on QT prolongation and torsade de pointes induced by intracoronary acetylcholine in the long QT syndrome.
    Furushima H; Niwano S; Chinushi M; Yamaura M; Taneda K; Washizuka T; Aizawa Y
    Am J Cardiol; 1999 Mar; 83(5):714-8. PubMed ID: 10080424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Iatrogenic torsade de pointes induced by thioridazine].
    Paoloni P; Ciliberti D; Blasi N; Capone P
    Minerva Cardioangiol; 1992 Jun; 40(6):245-9. PubMed ID: 1407620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
    Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
    Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.